Full Text View
Tabular View
No Study Results Posted
Related Studies
Nordic Adjuvant IFN Melanoma Trial
This study has been completed.
Study NCT01259934   Information provided by Karolinska Institutet

First Received on December 10, 2010.   Last Updated on December 13, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Melanoma
Adjuvant Therapy
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Interventions listed in this trial
Interferon-alpha2b - 1 year
Interferon-alpha2b - 2 years
Additional drug interventions recognized in this trial
Adjuvants, Immunologic
Interferon Alfa-2a
Interferon Alfa-2b
Interferon-alpha
Interferons
Reaferon
More general drug interventions related to this trial
Alcohol Deterrents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Central Nervous System Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Karolinska Institutet
Merck


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services